Image of a molecule

Galecto Biotech Accelerates Financing and Secures SEK 40 Million

Current investors of Galecto Biotech AB have confirmed the early release of additional funding to the company, which will enable acceleration of the development of its key drug candidates. The investor syndicate composed of four VCs with strong biotech records (Novo Seeds, MS Ventures, Sunstone Capital, and SEED Capital) continues to express strong confidence in Galecto Biotech’s portfolio of new promising Galectin Modulators